Topics:

Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

TOKYO, Japan—Eisai Co. Ltd and Eisai Corporation of North American (Woodcliff Lake, New Jersey) have signed a definitive agreement to acquire Morphotek (Exton, Pennsylvania) for $325 million. The acquisition is pending subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Morphotek develops therapeutic monoclonal antibodies and is evaluating two in early-stage clinical trials. Eisai's portfolio of oncology drugs currently includes small-molecule anticancer agents.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.